{
    "2021-06-04": [
        [
            {
                "time": "2021-06-04",
                "original_text": "贝达药业：埃克替尼术后辅助治疗适应症获得药品注册证书 将对公司营收带来积极影响",
                "features": {
                    "keywords": [
                        "贝达药业",
                        "埃克替尼",
                        "术后辅助治疗",
                        "药品注册证书",
                        "营收"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2021-06-04",
                "original_text": "贝达药业：盐酸埃克替尼片获得药品注册证书",
                "features": {
                    "keywords": [
                        "贝达药业",
                        "盐酸埃克替尼片",
                        "药品注册证书"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2021-06-04",
                "original_text": "贝达药业：盐酸埃克替尼片（商品名：凯美纳?）术后辅助治疗适应症获药品注册证",
                "features": {
                    "keywords": [
                        "贝达药业",
                        "盐酸埃克替尼片",
                        "凯美纳",
                        "术后辅助治疗",
                        "药品注册证"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2021-06-04",
                "original_text": "重磅！贝达药业埃克替尼术后辅助治疗获批上市",
                "features": {
                    "keywords": [
                        "贝达药业",
                        "埃克替尼",
                        "术后辅助治疗",
                        "获批上市"
                    ],
                    "sentiment_score": 0.95,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2021-06-04",
                "original_text": "午间公告2021年6月4日星期五",
                "features": {
                    "keywords": [],
                    "sentiment_score": 0.0,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2021-06-04",
                "original_text": "贝达药业(300558.SZ)：埃克替尼术后辅助治疗适应症获批",
                "features": {
                    "keywords": [
                        "贝达药业",
                        "埃克替尼",
                        "术后辅助治疗",
                        "适应症",
                        "获批"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2021-06-04",
                "original_text": "2021年医药生物行业半年度策略报告：乘风破浪会有时 辅助生殖新机遇",
                "features": {
                    "keywords": [
                        "医药生物",
                        "行业策略",
                        "辅助生殖",
                        "新机遇"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            }
        ]
    ]
}